Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the transaction, the insider owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

• On Friday, May 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00.
• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA opened at $68.86 on Tuesday. Oruka Therapeutics, Inc. has a 52 week low of $10.77 and a 52 week high of $91.00. The company has a market capitalization of $4.15 billion, a PE ratio of -35.49 and a beta of -0.25. The company has a 50 day moving average price of $63.71 and a two-hundred day moving average price of $44.31.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently made changes to their positions in ORKA. Goldman Sachs Group Inc. bought a new stake in shares of Oruka Therapeutics during the first quarter worth $2,505,000. JPMorgan Chase & Co. increased its position in shares of Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after acquiring an additional 13,115 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics during the second quarter worth $28,000. Rhumbline Advisers bought a new stake in shares of Oruka Therapeutics during the second quarter worth $320,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Oruka Therapeutics during the second quarter worth $96,000. Institutional investors own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ORKA has been the subject of several recent analyst reports. Barclays upped their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. UBS Group upped their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Finally, Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.